Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01153763 · ClinicalTrials.gov registry record · Phase 2
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT01153763 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 92 participants.
The verdict
NCT01153763, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
BRF113710 is a Phase II, single-arm, open-label study to assess the efficacy, safety, and tolerability of GSK2118436 administered twice daily as a single agent in subjects with BRAF mutant metastatic melanoma. Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
Interventions
- DRUG GSK2118436
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2010-08-09 |
| Est. Completion | 2016-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01153763
The ClinicalTrials.gov registry entry for NCT01153763 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK2118436 is the first listed.
NCT01153763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01153763 about?
NCT01153763 is a clinical study titled "A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma". BRF113710 is a Phase II, single-arm, open-label study to assess the efficacy, safety, and tolerability of GSK2118436 administered twice daily as a single agent in subjects with BRAF mutant metastatic melanoma. Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until dis...
What is the current status of trial NCT01153763?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2010-08-09. Estimated completion is 2016-06-01.
What interventions are being tested in trial NCT01153763?
The interventions under investigation include: GSK2118436 (DRUG).
Who is sponsoring clinical trial NCT01153763?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.